Daniel H. Katz

I am an Advanced Heart Failure and Transplant Cardiology physician at Stanford University.

I am interested in disease heterogeneity, particularly in advanced heart failure. How do we better understand the various pathophysiologic processes that result in the clinical syndrome of heart failure? Can we leverage the ever growing volumes of data to identify clinically important subgroups, and can knowledge of these subgroups help us better choose disease-modifying therapies?